AI-generated research brief — verify at source
Camrelizumab Plus CAPOX Improves Survival Over Chemotherapy Alone in Advanced Gastric Cancer
In HER2-negative unresectable or metastatic gastric and gastro-oesophageal junction adenocarcinoma, adding camrelizumab to CAPOX chemotherapy followed by camrelizumab-based maintenance extended median overall survival to 15.0 months versus a shorter duration with chemotherapy alone in the PD-L1 positive population, with a statistically significant survival benefit. The finding positions camrelizumab-containing regimens as a meaningful advance in this difficult-to-treat setting, though the incremental benefit of adding apatinib during maintenance remains uncertain.
What Was Studied
This trial investigated whether combining the PD-1 inhibitor camrelizumab with standard CAPOX chemotherapy (capecitabine plus oxaliplatin), followed by camrelizumab-based maintenance therapy, could extend overall survival compared with CAPOX alone as front-line treatment for HER2-negative, locally advanced or metastatic gastric or gastro-oesophageal junction (G/GEJ) adenocarcinoma — a population with historically poor outcomes and limited systemic treatment options.
How It Was Studied
This was a randomised, open-label, phase 3 trial conducted across 75 hospitals in China, enrolling patients between March 2019 and August 2021. A total of 885 adults aged 18 or older with previously untreated, HER2-negative, unresectable locally advanced or metastatic G/GEJ adenocarcinoma were enrolled. Participants were assigned in a 2:2:1 ratio to receive camrelizumab plus CAPOX followed by camrelizumab plus apatinib (camre+CAPOX → camre+apa; n=352), CAPOX alone (n=349), or camrelizumab plus CAPOX followed by camrelizumab monotherapy maintenance (camre+CAPOX → camre; n=177). Randomisation was stratified by ECOG performance status, presence of peritoneal metastasis, and PD-L1 combined positive score (CPS). Notably, the third arm was introduced partway through enrolment, and comparisons involving it were pre-specified as descriptive rather than confirmatory. The primary endpoint was overall survival assessed in both the PD-L1 positive subgroup (CPS >1) and the overall treated population.
What Was Observed
- Camre+CAPOX followed by camre+apa significantly extended overall survival compared with CAPOX alone in the PD-L1 positive population, with a median of 15.0 months in the immunotherapy arm versus a shorter median in the chemotherapy arm. At data cutoff, 454 of 592 patients (76.7%) in the PD-L1 positive group had died, providing a mature dataset for this primary analysis.
- A similar overall survival benefit was observed in the overall treated population, where 709 of 878 patients (80.8%) had died at the time of data cutoff, reinforcing that the benefit was not confined to PD-L1 selected patients, though the magnitude of the effect in CPS-unselected patients may differ.
- The descriptive comparison of camre+CAPOX followed by camre versus camre+CAPOX followed by camre+apa showed no additional survival advantage from adding the anti-angiogenic agent apatinib during maintenance, while grade ≥3 treatment-related adverse events and treatment discontinuations were more frequent in the apatinib-containing arm, suggesting a less favourable risk-benefit profile for that combination.
- Safety signals were higher with apatinib-containing maintenance, with increased rates of severe toxicity and treatment discontinuation compared with both the camrelizumab maintenance-only arm and the chemotherapy control, underscoring the added tolerability burden of dual-agent maintenance.
Why This Matters
Front-line treatment options for HER2-negative advanced G/GEJ adenocarcinoma have been an active area of investigation, particularly following approvals of other PD-1/PD-L1 inhibitors such as nivolumab and pembrolizumab in similar populations. This trial adds camrelizumab — a PD-1 inhibitor more extensively studied in Asian populations — to the roster of agents with phase 3 survival data in this setting, and importantly demonstrates that maintenance with camrelizumab alone after induction chemotherapy may capture the survival benefit without the additional toxicity of an anti-angiogenic partner.
How to Read This Result
The trial was conducted entirely in China and enrolled a predominantly Asian patient population, which may limit direct extrapolation of both efficacy and safety findings to other ethnic or geographic groups.
Limitations
The abstract does not explicitly report study limitations. However, several methodological features warrant attention: the open-label design introduces potential performance bias; the third treatment arm was added mid-enrolment with a smaller sample size and its comparisons were descriptive only, limiting inferential strength; and the entirely China-based population may affect generalisability to non-Asian patients.